BSL-3 CONTRACT INFECTIOUS DISEASE RESEARCH SERVICES

With ample state-of-the-art BSL-3 laboratory spaces and a highly skilled team of experts, we provide a wide range of standard and custom virology testing, assay development, high-titer virus stocks and reverse genetics services. We also have a dedicated BSL-3 Campaign Room available for highly sensitive projects. Our team brings a consultative approach to each engagement and we collaborate with you to build a custom program for your specific needs.

Our full range of virology laboratory services is available for any BSL-3 agent. We are also in the process of adding Select Agents to our portfolio.

LEARN MORE ABOUT OUR BSL-3 INFECTIOUS DISEASE CRO

COMMON PATHOGENS OF INTEREST

Our team is highly experienced with a wide variety of common and obscure BSL-3 pathogens. We have deep expertise with respiratory agents, including SARS CoV-2 and MTB, as well as other emergent threats like Avian Influenza and Mpox. We also support research for HIV and mosquito-borne pathogens such as West Nile Virus and Chikungunya.

SARS-CoV-2

Microbiologics has been supporting SARS-CoV-2 research since the beginning of the global pandemic. We offer a range of virology CRO services for SARS-CoV-2 including custom viral stock production and high-throughput antiviral testing.

We provide high titer live or inactivated whole virus SARS-CoV-2 variants for research. Additionally, our team is skilled at modifying the genome of SARS-CoV-2 to develop live, recombinant virus. We can change something as small as a nucleotide or make a modification as large as swapping an entire spike gene within a given viral backbone.

With multiple BSL-3 laboratories, we offer a variety of high-throughput antiviral testing services for all available SARS-CoV-2 variants. We can test your antivirals using advanced 3D cell system models. We can also perform studies to look for escape mutants with your antiviral or therapeutic. In these experiments a sequencing report is generated listing the genetic profile of viral genomes using Next Generation Sequencing (NGS).

We also offer a high-throughput, validated, ELISA-based Microneutralization Assay for SARS-CoV-2 virus* for determining MN50 titers of sera tested against the WT SARS-CoV-2 WA-1/2020 variant. If your research requires the use of different SARS-CoV-2 variants, we will work with you to develop a custom microneutralization assay based on your needs.

Mpox (Monkeypox)

Microbiologics offers inactivated human Mpox virus for the development and validation of assays, vaccines, and therapies. Using a validated inactivation process, we are able to provide non-infectious RUO biomaterials which allow our partners to perform research critical to the global response of the Mpox outbreak without requiring an in-house BSL-3 laboratory. We also offer assay services in our BSL-3 to quantify infectious Mpox or help clients develop testing platforms where use of the infectious Mpox is required.

HIV

According to the World Health Organization (WHO), an estimated 38.4 million people are living with HIV worldwide as of 2021. Microbiologics is committed to supporting researchers working to discover novel biologics for preventing and treating HIV. We provide HIV type 1 and type 2 virus stocks. We can also generate HIV -1 tagged with GFP reporter, or custom infectious and non-infectious HIV clones built to specification using reverse genetics systems.

Additionally, we offer standard and custom testing services to measure HIV infectivity titers. Our methods include CPE observation-based TCID50 assay, luciferase-based assay and more. For pre-clinical and clinical studies of HIV neutralizing antibodies, antiviral drugs, and vaccines, we provide HIV microneutralization and antiviral assay services.

Mycobacterium tuberculosis (MTB)

MTB is responsible for more deaths worldwide than any other infectious agent with 10.6 million new cases and 1.6 million deaths in 2022. Although research into new agents for the treatment of MTB is an active area, there are comparatively few laboratories capable of supporting this development due to pathogen’s BSL-3 classification. MTB is commonly multi-drug resistant (MDR) or extensively drug resistant (XDR) and is inherently difficult to work with, primarily due to slow generation times.

Microbiologics is ready to assist industry with primary and secondary profiling for MTB development. We have validated broth microdilution susceptibility testing of MTB using custom frozen panels. These panels can be made to suit your screening needs with any number of investigational compounds alongside relevant comparators. We have a variety of MTB strains available for primary profiling, including susceptible and resistant isolates.

Tropical Viruses

Microbiologics supports research on emerging tropical-disease viruses and vector-borne viruses for the development of diagnostic technologies, vaccines and therapeutics. Our team of experts have experience with viruses such as Chikungunya and West Nile which further complement our portfolio of BSL-2 tropical viruses such as Dengue and Zika.

OUR CURRENT BSL-3 SERVICES INCLUDE: